List of Excipients in Branded Drug MELOXICAM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Avondale Pharmaceuticals LLC	MELOXICAM	meloxicam	71740-339	CITRIC ACID MONOHYDRATE
Avondale Pharmaceuticals LLC	MELOXICAM	meloxicam	71740-339	GLYCERIN
Avondale Pharmaceuticals LLC	MELOXICAM	meloxicam	71740-339	HYDROXYETHYL CELLULOSE

Generic Drugs Containing MELOXICAM

Company	Ingredient	NDC	Excipient
Liberty Pharmaceuticals Inc	meloxicam	0440-5841	CELLULOSE, MICROCRYSTALLINE
Liberty Pharmaceuticals Inc	meloxicam	0440-5841	CROSPOVIDONE
Liberty Pharmaceuticals Inc	meloxicam	0440-5841	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in MELOXICAM?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
1	ANHYDROUS LACTOSE

Meloxicam Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Meloxicam is a mature NSAID with broad generic availability and limited composition-of-matter protection. Commercial value has shifted from the active ingredient to differentiated delivery: low-dose capsules, orally disintegrating tablets, oral suspension, and parenteral products. The strongest excipient opportunities address meloxicam’s poor water solubility, dose flexibility, rapid disintegration, taste, physical stability, and injectable compatibility.

What is the commercial position of meloxicam?

Meloxicam is a preferential cyclooxygenase-2 NSAID used for osteoarthritis, rheumatoid arthritis, and short-term acute pain. U.S. products include tablets, capsules, oral suspension, orally disintegrating tablets, and injectable formulations.

Product or dosage form	Typical strength	Commercial role	Key formulation issue
Meloxicam tablets	7.5 mg, 15 mg	High-volume generic market	Low aqueous solubility and variable dissolution
Meloxicam oral suspension	7.5 mg/5 mL	Pediatric and swallowing-impaired patients	Sedimentation, redispersibility, taste, preservative system
Vivlodex capsules	5 mg, 10 mg	Low-dose osteoarthritis treatment	Dose differentiation and capsule fill uniformity
Qmiiz ODT	7.5 mg, 15 mg	Rapid oral administration without water	Disintegration, taste masking, friability
Anjeso injection	30 mg/mL	Hospital acute-pain market	Solubility, particulate control, container compatibility

Mobic, the originator product, received U.S. approval in 2000. Generic meloxicam tablets and oral suspension products subsequently entered the market after loss of the original product protection. Vivlodex, Qmiiz ODT, and Anjeso created later commercial positions through dosage-form and clinical-use differentiation rather than through new meloxicam molecular protection (U.S. Food and Drug Administration [FDA], 2000, 2015, 2020a, 2020b).

What excipient properties are most important for meloxicam?

Meloxicam is a weak acid with pH-dependent solubility. Its low intrinsic aqueous solubility can limit dissolution, particularly from conventional immediate-release tablets. The formulation target is usually rapid and reproducible dissolution without increasing gastrointestinal exposure beyond the intended dose.

The principal excipient functions are:

1. Improving wetting and dissolution.
2. Maintaining content uniformity at low dose.
3. Controlling tablet breakup and powder flow.
4. Masking bitterness in liquid and ODT products.
5. Stabilizing suspensions.
6. Maintaining injectable solubility and sterility.
7. Preserving chemical and physical stability during storage.

Solubility-enhancing excipients

Candidate excipient classes include:

• Surfactants such as sodium lauryl sulfate, polysorbates, poloxamers, and selected nonionic wetting agents.
• Alkalinizing or buffering agents, including bicarbonates, carbonates, phosphates, and selected organic bases.
• Hydrophilic polymers such as povidone, copovidone, hydroxypropyl cellulose, and polyethylene glycol.
• Cyclodextrins and cyclodextrin derivatives.
• Lipid-based vehicles, including medium-chain triglycerides and self-emulsifying systems.
• Colloidal silica and other carriers for improved powder wetting.

The commercial advantage depends on achieving dissolution improvement with a low excipient burden. Excess surfactant can increase tablet sensitivity to humidity, alter disintegration, or create gastrointestinal tolerability concerns. Alkaline pH modifiers can improve dissolution but may affect chemical stability, taste, and compatibility with packaging.

Disintegrants and compression aids

For tablets and ODTs, the most relevant excipients are:

• Crospovidone.
• Croscarmellose sodium.
• Sodium starch glycolate.
• Microcrystalline cellulose.
• Mannitol.
• Lactose monohydrate.
• Dibasic calcium phosphate.
• Low-substituted hydroxypropyl cellulose.

Crospovidone and croscarmellose sodium are commercially attractive for rapid breakup. Mannitol is useful in ODTs because it provides a cooling mouthfeel and acceptable compressibility. Microcrystalline cellulose supports tablet strength but can slow disintegration if used at excessive levels.

Suspension excipients

Meloxicam oral suspension requires a controlled particle-size distribution and a vehicle that remains redispersible after storage. Relevant excipients include:

• Xanthan gum.
• Hypromellose.
• Sodium carboxymethylcellulose.
• Microcrystalline cellulose and carboxymethylcellulose sodium combinations.
• Glycerol or sorbitol.
• Polysorbates.
• Benzoate or sorbate preservatives, where compatible with the formulation and regulatory requirements.
• Sweeteners and flavors.

A commercially robust suspension should redisperse with limited shaking, resist caking, deliver a uniform dose through the intended measuring device, and remain acceptable after repeated opening. The formulation must also control microbial growth without creating pH or taste problems.

How should an excipient platform be designed for meloxicam tablets?

A conventional tablet platform should prioritize dissolution, manufacturability, and low cost. The strongest design is typically a wet-granulated or dry-granulated composition that combines a hydrophilic diluent, a superdisintegrant, a wetting agent, and a film coat.

Formulation objective	Preferred excipient strategy	Main development risk
Improve wetting	Low level of surfactant or hydrophilic polymer	Overlubrication and dissolution delay
Increase dissolution	Amorphous dispersion or pH-modified granule	Recrystallization and stability loss
Improve flow	Silicified microcrystalline cellulose or colloidal silica	Segregation and content-uniformity failure
Accelerate disintegration	Crospovidone or croscarmellose sodium	Reduced hardness or friability
Protect from moisture	Film coating and high-barrier packaging	Slower disintegration if coating is excessive
Support dose flexibility	Common granulation with proportional strengths	Nonlinear dissolution across strengths

A low-cost generic product should avoid unnecessary proprietary excipient systems unless they produce a measurable advantage in dissolution, stability, or process yield. The most defensible formulation work is likely to involve a specific combination of particle engineering, granulation conditions, excipient ratios, and dissolution performance rather than a broad claim to a conventional excipient class.

What excipients are most suitable for meloxicam orally disintegrating tablets?

ODT products compete on administration convenience, not simply on active-ingredient equivalence. A successful meloxicam ODT requires rapid disintegration, low friability, acceptable mouthfeel, and effective bitterness control.

A practical ODT architecture may include:

• Mannitol as the principal diluent and sensory carrier.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Colloidal silicon dioxide for flow.
• Aspartame, sucralose, acesulfame potassium, or another suitable sweetener.
• Mint, citrus, berry, or neutral flavor systems.
• A polymeric taste masker or coated meloxicam particles.
• Magnesium stearate at a controlled level.

Taste masking is the principal differentiator. Meloxicam’s bitterness can become more pronounced when the product disperses in the mouth. Coating the active with a pH-sensitive or water-insoluble polymer can reduce immediate taste exposure, but excessive coating can delay dissolution and complicate bioequivalence.

Commercial opportunities include:

• A lower-friability ODT for institutional dispensing.
• A sugar-free ODT for chronic-use patients.
• A preservative-free unit-dose ODT.
• A rapidly disintegrating product with a validated in-vitro performance advantage.
• A pediatric-oriented dosage form, subject to pediatric safety and dosing requirements.

What excipients are appropriate for meloxicam oral suspension?

The suspension market is smaller than the tablet market but has higher formulation barriers. The product must control sedimentation without producing a hard cake. A structured vehicle based on xanthan gum or a microcrystalline cellulose-carboxymethylcellulose system can provide acceptable suspendability and redispersibility.

Critical development tests include:

• Assay uniformity after standing.
• Dose delivery through the supplied oral syringe or cup.
• Redispersibility after defined storage intervals.
• Viscosity at multiple shear rates.
• Particle-size growth during storage.
• Preservative effectiveness.
• Container closure compatibility.
• Stability after repeated opening.

Taste masking can use sweeteners, flavors, and polymer-coated active particles. High sugar content may improve palatability but can reduce suitability for some patients and complicate positioning. A sugar-free, alcohol-free suspension with a calibrated oral syringe provides a clearer commercial proposition than a conventional flavored product.

What formulation strategy is suitable for meloxicam injectable products?

Parenteral meloxicam requires a materially different excipient strategy. The formulation must maintain solubility at the target concentration while meeting requirements for sterility, particulate matter, osmolality, pH, extractables, and container compatibility.

Relevant excipient classes may include:

• Cosolvents such as polyethylene glycol or propylene glycol.
• pH-adjusting agents.
• Tonicity agents.
• Antioxidants where justified by degradation pathways.
• Chelating agents where trace metals contribute to instability.
• Preservatives only where the intended presentation permits them.

An injectable product has higher technical and regulatory barriers than an oral generic. Commercial opportunities include ready-to-use presentations, smaller-volume administration, reduced preparation steps, and improved compatibility with hospital medication systems. The principal risks are precipitation during dilution, adsorption to infusion components, container interaction, and local tolerability.

What patents protect meloxicam formulations?

The original meloxicam composition-of-matter protection has expired, and meloxicam is widely available as an authorized generic and prescription generic. Current commercial protection is more likely to arise from:

• Specific dosage-form compositions.
• Low-dose capsule formulations.
• Orally disintegrating tablet compositions.
• Injectable formulations.
• Particle-size or crystal-form controls.
• Taste-masked particles.
• Manufacturing processes.
• Fixed-dose combinations.
• Method-of-use claims tied to particular patient populations or dosing regimens.

FDA Orange Book entries should be evaluated by NDA and dosage form because patent status differs between Mobic, Vivlodex, Qmiiz ODT, and Anjeso. A patent listed for a branded dosage form does not automatically block a conventional meloxicam tablet ANDA.

What is the Orange Book status of meloxicam?

The commercial landscape contains both legacy branded NDAs and generic ANDAs. The relevant regulatory distinction is:

Regulatory pathway	Commercial implication
Conventional tablet ANDA	Usually faces mature generic competition
Oral suspension ANDA	Higher formulation and device complexity
Capsule product under a branded NDA	May retain dosage-form or method-of-use differentiation
ODT NDA	May rely on formulation patents and regulatory exclusivity
Injectable NDA	Requires sterile manufacturing and parenteral CMC evidence
505(b)(2) product	Can support a differentiated delivery system with reliance on existing meloxicam data

The Orange Book should be analyzed for listed patents, use codes, pediatric exclusivity, and regulatory exclusivity attached to each NDA. FDA approval of a product does not establish that all related patents have expired; it establishes the regulatory status of that specific application (FDA, n.d.-a).

When does meloxicam lose exclusivity and what is the generic entry risk?

Meloxicam’s core generic-entry risk is already realized for standard oral tablets. The remaining barriers are product-specific rather than molecule-wide.

Product segment	Generic-entry risk	Main barrier
7.5 mg and 15 mg tablets	High	Low technical complexity and mature manufacturing
Oral suspension	Moderate	Physical stability and dose uniformity
5 mg and 10 mg low-dose capsules	Moderate	Dose differentiation and product-specific patents
ODT	Moderate	Taste masking, disintegration, and formulation claims
Injectable	Lower near term than tablets	Sterile processing, solubility, and hospital procurement
Novel combination product	Variable	Clinical, regulatory, and patent requirements

Paragraph IV risk is most relevant to branded dosage-form products with listed formulation or method-of-use patents. A generic applicant can challenge listed patents by asserting invalidity, unenforceability, or non-infringement. For conventional meloxicam tablets, the economic incentive for a Paragraph IV filing is limited unless the target product has meaningful market share or pricing power.

No biosimilar pathway applies to meloxicam because it is a chemically synthesized small molecule. Competition proceeds through ANDA or, for a differentiated product, potentially a 505(b)(2) application.

Which companies are challenging meloxicam products?

Generic competition is broad, with multiple manufacturers marketing meloxicam tablets and other oral presentations. Public commercial records commonly identify manufacturers such as Zydus, Dr. Reddy’s, Camber, Hikma, Solco, Rising, Teva, and other U.S. generic suppliers, depending on product and distribution period.

A company-by-company Paragraph IV assessment must be separated from ordinary ANDA competition. An ANDA holder may enter after certification, patent expiration, settlement, or a court decision. Generic availability alone does not establish that the applicant made a Paragraph IV challenge.

What licensing and partnership opportunities exist for meloxicam excipients?

The strongest licensing opportunities are technology-led rather than active-ingredient-led.

Excipient and formulation licensing targets

Potential partners include:

• Nanocrystal technology providers.
• Amorphous solid-dispersion developers.
• Taste-masking specialists.
• ODT platform owners.
• Suspension and pediatric-delivery companies.
• Sterile injectable formulation manufacturers.
• Excipient suppliers with proprietary grades and regulatory files.
• Contract development and manufacturing organizations with validated meloxicam processes.

A license is most defensible where it provides a package of formulation know-how, scale-up data, analytical methods, and patent rights. A single off-the-shelf excipient is less likely to support premium economics because multiple pharmacopeial alternatives may exist.

Commercial white spaces

1. A stable, sugar-free oral suspension with an integrated dosing syringe.
2. A low-cost ODT with robust taste masking and high mechanical strength.
3. A modified-release product that reduces dosing frequency, subject to clinical requirements.
4. A fixed-dose combination with a complementary analgesic, subject to safety and regulatory review.
5. A hospital-ready injectable presentation with reduced preparation time.
6. A veterinary meloxicam product with improved palatability and dosing accuracy.
7. A product optimized for patients with dysphagia or reduced water access.

How strong is the meloxicam patent estate?

The patent estate is strong only in selected delivery segments. It is weak for the basic active ingredient and conventional immediate-release tablets because of extensive generic competition and the age of the molecule.

Patent category	Relative strength	Commercial assessment
Core meloxicam molecule	Low	Expired or commercially exhausted
Conventional tablet composition	Low to moderate	Design-around options are numerous
ODT composition	Moderate	Strength depends on narrow excipient and performance claims
Taste-masked particles	Moderate to strong	More difficult to design around if claims cover particle architecture
Low-dose capsule	Moderate	Dose and clinical positioning may support differentiation
Injectable formulation	Moderate	CMC complexity increases practical barriers
Manufacturing process	Variable	Stronger if process produces a measurable product attribute
Method of use	Variable	Vulnerable to label carve-outs and non-infringing use

The most valuable intellectual property should claim a reproducible relationship between excipient composition, particle engineering, dissolution, taste, stability, and clinical use. Broad claims to common excipients are vulnerable to prior art and obviousness attacks.

What revenue exposure does meloxicam create for manufacturers?

For generic manufacturers, standard meloxicam tablets usually offer volume but limited pricing power. Revenue exposure is concentrated in:

• High-volume retail prescriptions.
• Preferred formulary contracts.
• Low manufacturing cost.
• Reliable supply.
• Multiple strength availability.
• Integrated tablet and suspension portfolios.

Branded or differentiated products have greater exposure to patent expiry, formulary substitution, and generic launch. The commercial value of a new excipient platform should therefore be measured against achievable differentiation, not against total meloxicam prescription volume.

A formulation that reduces manufacturing cost by improving yield, compression speed, or content uniformity may generate more durable value than a marginal dissolution improvement. For hospital products, reduced preparation time and fewer handling steps can support pricing even when the active ingredient is generic.

Key Takeaways

• Meloxicam’s molecule-level protection is exhausted; the opportunity is in delivery and manufacturing.
• Tablets are a mature, price-competitive generic segment.
• ODTs, low-dose capsules, oral suspensions, and injectables offer the clearest formulation differentiation.
• The principal technical challenge is improving dissolution without compromising stability, taste, or bioequivalence.
• Suspension products require strong control of redispersibility, dose uniformity, microbial protection, and palatability.
• Injectable products have higher barriers because of solubility, sterility, particulate, and container-compatibility requirements.
• The strongest patent strategy claims specific excipient combinations, particle attributes, performance parameters, or manufacturing outcomes.
• Biosimilar competition is irrelevant because meloxicam is a small-molecule drug.
• Commercial success depends more on formulation reliability, supply economics, and channel positioning than on active-ingredient exclusivity.

FAQs

Can a new meloxicam excipient formulation receive FDA approval without new clinical trials?

Often, yes, if the product demonstrates pharmaceutical equivalence and bioequivalence through an ANDA. A materially different delivery system or route may require a 505(b)(2) application and additional clinical evidence.

Which excipient is best for improving meloxicam dissolution?

No single excipient is universally superior. Surfactants, pH modifiers, hydrophilic polymers, cyclodextrins, and particle-engineering approaches should be screened against dissolution, stability, manufacturability, and bioequivalence requirements.

Is meloxicam suitable for a pediatric formulation?

A liquid suspension or low-strength ODT may support pediatric dosing, but pediatric development requires appropriate safety, dose-flexibility, taste, device, and regulatory data. Meloxicam labeling and NSAID class risks remain central to product design.

Can a meloxicam ODT be protected by patents?

Yes. Protection may cover the excipient matrix, taste-masked particles, disintegration profile, manufacturing process, or defined dissolution characteristics. Patent strength depends on claim scope and prior art.

What is the most attractive commercial meloxicam dosage form?

The best opportunity is generally a differentiated dosage form with a clear user or channel benefit, such as a stable sugar-free suspension, a robust taste-masked ODT, or a hospital-ready injectable. Conventional tablets offer the lowest technical risk but also the weakest pricing power.

References

1. U.S. Food and Drug Administration. (2000). Mobic (meloxicam) tablets prescribing information.
2. U.S. Food and Drug Administration. (2015). Vivlodex (meloxicam) capsules prescribing information.
3. U.S. Food and Drug Administration. (2020a). Anjeso (meloxicam injection) prescribing information.
4. U.S. Food and Drug Administration. (2020b). Qmiiz ODT (meloxicam orally disintegrating tablets) prescribing information.
5. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database.
7. DailyMed. (n.d.). Meloxicam drug labels and dosage-form information. National Library of Medicine.
8. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.